Incidence of thromboembolic stroke and of major bleeding in patients with atrial fibrillation and chronic kidney disease treated with and without warfarin

International Journal of Nephrology and Renovascular Disease

Volumn 2, Issue , 2009, Pages 33-37

  Lai, Hoang M ^a   Aronow, Wilbert S ^a   Kalen, Phoenix ^a   Adapa, Sreedhar ^a   Patel, Kaushal ^a   Goel, Arvind ^a   Vinnakota, Ravi ^a   Chugh, Savneek ^a   Garrick, Renee ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Anticoagulants; Atrial fibrillation; Chronic kidney disease; Major bleeding; Thromboembolic stroke

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN;

AGED; ARTICLE; BLEEDING; CHRONIC KIDNEY DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; DISEASE PREDISPOSITION; FEMALE; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEMODIALYSIS; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; RISK ASSESSMENT; STROKE; TRANSIENT ISCHEMIC ATTACK; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 77953365067     PISSN: None     EISSN: 11787058     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Abe S, Yoshizawa M, Nakanishi N, et al. Electrocardiographic abnormalities in patients receiving hemodialysis. Am Heart J. 1996;131:1137-1144.
2. Atar I, Konas D, Acikel S, et al. Frequency of atrial fibrillation and factors related to its development in dialysis patients. Int J Cardiol. 2006;106:47-51.
3. Vazquez E, Sanchez-Perales C, Borrego F, et al. Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis. Am Heart J. 2000;140:886-890.
4. Das M, Aronow WS, McClung JA, Belkin RN. Increased prevalence of coronary artery disease, silent myocardial ischemia, complex ventricular arrhythmias, atrial fibrillation, left ventricular hypertrophy, mitral annular calcium, and aortic valve calcium in patients with chronic renal insufficiency. Cardiol Rev. 2006;14:14-17.
5. Fabbian F, Catalano C, Lambertini D, et al. Clinical characteristics associated to atrial fibrillation in chronic hemodialysis patients. Clin Nephrol. 2000;54:234-239.
6. Genovesi S, Pogliani D, Faini A, et al. Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients. Am J Kidney Dis. 2005;46:897-902.
7. Vazquez E, Sanchez-Perales C, Lozano C, et al. Comparison of prognostic value of atrial fibrillation versus sinus rhythm in patients on long-term hemodiálysis. Am J Cardiol. 2003;92:868-871.
8. Vazquez-Ruiz de Castroviejoa E, Sanchez-Perales C, Lozano-Cabezas C, et al. [Incidence of atrial fibrillation in hemodialysis patients. A prospective long-term follow-up study]. Rev Esp Cardiol. 2006;59:779-784.
9. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med. 1990;323:1505-1511.
10. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449-1457.
11. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet. 1996;348:633-638.
12. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet. 1993;342:1255-1262.
13. Peterson P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. Lancet. 1989;1:175-179.
14. Preliminary report of the Stroke Prevention in Atrial Fibrillation Study. N Engl J Med. 1990;322:863-868.
15. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation. 1991;84:527-539.
16. Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol. 1991;18:345-355.
17. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med. 1992;327:1406-1412.
18. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;343:687-691.
19. Gullov AL, Koefoed BG, Petersen P, et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation. Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med. 1998;158:1513-1521.
20. Aronow WS, Ahn C, Kronzon I, Gutstein H. Incidence of new thromboembolic stroke in persons ≥62 years old with chronic atrial fibrillation treated with warfarin versus aspirin. J Am Geriatr Soc. 1999;47:366-368.
21. Aronow WS, Ahn C, Kronzon I, Gutstein H. Effect of warfarin versus aspirin on the incidence of new thromboembolic stroke in older persons with chronic atrial fibrillation and abnormal and normal left ventricular ejection fraction. Am J Cardiol. 2000;85:1033-1035.
22. Aronow WS. Acute and chronic management of atrial fibrillation in patients with late-stage CKD. Am J Kidney Dis. 2009;53:701-710.
23. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine. A new predictive equation. Ann Intern Med. 1999;130:461-470.
24. National Kidney Foundation: Kidney Disease Outcome Quality Initiative (K/DOQI) clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(suppl 1):S1-S266.
25. Ruioz-Nodar JM, Marin F, Hurtado JA, et al. Anticoagulant therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation. J Am Coll Cardiol. 2008;51:818-835.
26. Abbott KC, Trespalacios FC, Taylor AJ, Agodoa LY. Atrial fibrillation in chronic dialysis patients in the United States: risk factors for hospitalization and mortality. BMC Nephrol. 2003;4:1.
27. Korantzopoulos P, Kokkoris S, Liu T, Protopsaltis I, Li G, Goudevenos JA. Atrial fibrillation in end-stage renal disease. Pacing Clin Electrophysiol. 2007;30:1391-1397.
28. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: Executive summary. J Am Coll Cardiol. 2001;38:1231-1265.
29. Vazquez E, Sanchez-Perales C, Garcia-Cortes J, et al. Ought dialysis patients with atrial fibrillation be treated with oral anticoagulants? Int J Cardiol. 2003;87:135-139.
30. Wright JR, Kalra PA. Ought dialysis patients with atrial fibrillation be treated with oral anticoagulants? Int J Cardiol. 2003;87:139-141.
31. Elliott MJ, Zimmerman D, Holden RM. Warfarin anticoagulation in hemodialysis patients: A systematic review of bleeding rates. Am J Kidney Dis. 2007;50:433-440.
32. Quinn RR, Naimark DM, Oliver MJ, et al. Should hemodialysis patients undergo systemic anticoagulation? A cost-utility analysis. Am J Kidney Dis. 2007;50:421-432.
33. Abbott KC, Neff RT, Bohen EM, Narayan R. Anticoagulation for chronic atrial fibrillation in hemodialysis patients: which fruit from the decision tree? Am J Kidney Dis. 2007;50:345-348.